Rilapladib
2 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
2
Ongoing
0
Recruiting
0
Completed
1
Sites
27
Countries
6
Endpoints
35
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 35 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 0 of 35 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
No normalized metric codes are available for this asset.
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
2 of 2
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT01428453A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease | Rilapladib Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 30 | Feb 2013 | 1 | results |
| NCT02130661Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers | Rilapladib Alzheimer’s disease | Age 18-65 | Ph 1 | Withdrawn | 0 | Jan 2018 | - |
Showing 1-2 of 2 trials